Skip to main content
Growth hormone supplementation and psychosocial functioning to adult height in Turner syndrome: A questionnaire study of participants in the Canadian randomized trial
Frontiers in Endocrinology
  • Joanne F. Rovet, University of Toronto
  • Guy Van Vliet, University of Montreal
  • J. A. Curtis, Memorial University of Newfoundland
  • E. Cummings, Dalhousie University
  • S. R. Salisbury, Dalhousie University
  • F. Szots, Université Laval
  • K. Khoury, Université de Sherbrooke
  • R. Collu, University of Montreal
  • C. L. Deal, University of Montreal
  • C. Huot, University of Montreal
  • R. D. Barnes, Université McGill
  • H. J. Guyda, Université McGill
  • L. Legault, Université McGill
  • C. Polychronakos, Université McGill
  • C. Rodd, Université McGill
  • K. A. Faught, University of Ottawa
  • S. E. Lawrence, University of Ottawa
  • M. L. Lawson, University of Ottawa
  • D. S. Alexander, Queen’s University
  • D. Daneman, University of Toronto
  • J. D. Bailey, University of Toronto
  • R. M. Ehrlich, University of Toronto
  • K. Perlman, University of Toronto
  • E. Sochett, University of Toronto
  • A. B. MacMillan, McMaster University
  • F. J. Holland, McMaster University
  • J. A. Vander Meulen, McMaster University
  • C. L. Clarson, Western University
  • M. R.F. Jenner, Western University
Document Type
Publication Date
URL with Digital Object Identifier

Despite the long-held belief that growth hormone supplementation provides psychosocial benefits to patients with Turner syndrome (TS), this assumption has never been rigorously tested in a randomized control trial. As a sub-study of the Canadian growth-hormone trial, parent-, and patient-completed standardized questionnaires were used to compare 70 girls with TS who received injections (GH group) and 61 similarly followed untreated TS controls (C) on multiple facets of psychosocial functioning. Questionnaires were given (i) at baseline (session 1, mean age = 10.4 y), (ii) before estrogen therapy for puberty induction (session 2, mean age = 13.0 y), (iii) after 1 year of estrogen therapy (session 3, mean age = 14.4 y), and (iv) when growth stopped (session 4, mean age = 16.3 y). Groups were compared for multiple facets of psychosocial function within social, behavioral, self-esteem, and academic domains. Results were also correlated with indices of adult height. We found no global (i.e., across-session) group differences on any scales or subscales of the four domains. In both GH and C groups, age-related improvements were seen for social problems, externalizing behavior problems, and school functioning and age-related declines for social competence and social relations. Both parents and patients claimed GH received less teasing than C but C had more friends than GH. Results from analyses conducted within individual sessions showed that while GH at early sessions claimed to be more popular, more socially engaged, better adapted, and to have higher self-esteem than C, C was reported to be less anxious, depressed, and withdrawn than GH at adult height. The correlation analyses revealed different effects of adult height and height gain on outcome for the two groups. In GH, both height parameters were correlated with multiple parent- and/or self-reported indices from the four psychosocial domains, whereas in C, only adult height and two indices (viz., total self-concept and school functioning), were correlated. The observed modest gains in psychosocial functioning for patients with TS treated with GH highlight the need for alternative approaches to assist them in coping with the challenges of their condition.

Citation Information
Joanne F. Rovet, Guy Van Vliet, J. A. Curtis, E. Cummings, et al.. "Growth hormone supplementation and psychosocial functioning to adult height in Turner syndrome: A questionnaire study of participants in the Canadian randomized trial" Frontiers in Endocrinology Vol. 10 Iss. MAR (2019)
Available at: